Literature DB >> 19494177

Bile high-mobility group box 1 contributes to gut barrier dysfunction in experimental endotoxemia.

Runkuan Yang1, Keita Miki, Niku Oksala, Atsunori Nakao, Leena Lindgren, Meaghan E Killeen, Ari Mennander, Mitchell P Fink, Jyrki Tenhunen.   

Abstract

Lipopolysaccharide (LPS) is an important factor in sepsis. LPS given by intraperitoneal injection induces intestinal hyperpermeability and bacterial translocation in animals and stimulates hepatic Kupffer cells to release TNF-alpha into the bile. This study aims to test the hypothesis that in response to LPS stimulation, hepatic Kupffer cells and extrahepatic macrophages release a large amount of the inflammatory cytokine high-mobility group box 1 (HMGB1) into the bile and that bile containing HMGB1 contributes to gut barrier dysfunction in experimental endotoxemia. To test this, rat common bile ducts were catheterized and bile flow rate was monitored before and during the LPS administration. Eight hours after LPS challenge, anti-HMGB1 neutralizing antibody or nonimmune (sham) IgG was injected into the duodenal lumen of endotoxemic rats; normal mice were also gavaged with normal or endotoxemic rat bile (bile collected from LPS-treated rats). We found that after LPS challenge, the bile flow rate in rats was significantly decreased at the 4- to 12-h time points, TNF-alpha concentration in the bile was markedly elevated at the 3- to 4-h time points, and bile HMGB1 levels were significantly increased at the 8- to 12-h time points. Duodenal injection with anti-HMGB1 antibody reversed LPS-induced gut barrier dysfunction in rats. In addition, feeding endotoxemic rat bile to normal mice significantly increased both mucosal permeability and bacterial translocation. The increase in permeability and bacterial translocation was reversible following removal of HMGB1 from the endotoxemic rat bile. These findings document that bile HMGB1 mediates gut barrier dysfunction in experimental endotoxemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494177     DOI: 10.1152/ajpregu.00184.2009

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  25 in total

1.  Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis.

Authors:  Laura E Fredenburgh; Margarita M Suárez Velandia; Jun Ma; Torsten Olszak; Manuela Cernadas; Joshua A Englert; Su Wol Chung; Xiaoli Liu; Cynthia Begay; Robert F Padera; Richard S Blumberg; Stephen R Walsh; Rebecca M Baron; Mark A Perrella
Journal:  J Immunol       Date:  2011-10-03       Impact factor: 5.422

2.  Genomic and lipidomic analyses differentiate the compensatory roles of two COX isoforms during systemic inflammation in mice.

Authors:  Xinzhi Li; Liudmila L Mazaleuskaya; Laurel L Ballantyne; Hu Meng; Garret A FitzGerald; Colin D Funk
Journal:  J Lipid Res       Date:  2017-11-27       Impact factor: 5.922

Review 3.  Location is the key to function: HMGB1 in sepsis and trauma-induced inflammation.

Authors:  Meihong Deng; Melanie J Scott; Jie Fan; Timothy R Billiar
Journal:  J Leukoc Biol       Date:  2019-04-04       Impact factor: 4.962

4.  Total parenteral-nutrition-mediated dendritic-cell activation and infiltration into the small intestine in a rat model.

Authors:  Satoshi Hagiwara; Hideo Iwasaka; Junya Kusaka; Nobuhiko Asai; Tomohisa Uchida; Takayuki Noguchi
Journal:  J Anesth       Date:  2010-11-06       Impact factor: 2.078

5.  Protective Effects of Chymostatin on Paraquat-Induced Acute Lung Injury in Mice.

Authors:  Chen Yang; Hong-Wei Song; Wei Liu; Xue-Song Dong; Zhi Liu
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

6.  miR-130a and miR-212 Disrupt the Intestinal Epithelial Barrier through Modulation of PPARγ and Occludin Expression in Chronic Simian Immunodeficiency Virus-Infected Rhesus Macaques.

Authors:  Vinay Kumar; Joshua Mansfield; Rong Fan; Andrew MacLean; Jian Li; Mahesh Mohan
Journal:  J Immunol       Date:  2018-03-07       Impact factor: 5.422

Review 7.  High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation.

Authors:  Shu Zhu; Wei Li; Mary F Ward; Andrew E Sama; Haichao Wang
Journal:  Inflamm Allergy Drug Targets       Date:  2010-03

Review 8.  Targeting HMGB1 in inflammation.

Authors:  Huan Yang; Kevin J Tracey
Journal:  Biochim Biophys Acta       Date:  2009-12-03

9.  Blockade of high-mobility group box-1 ameliorates acute on chronic liver failure in rats.

Authors:  Xun Li; Li-Kun Wang; Lu-Wen Wang; Xiao-Qun Han; Fan Yang; Zuo-Jiong Gong
Journal:  Inflamm Res       Date:  2013-04-17       Impact factor: 4.575

10.  Lipopolysaccharide-induced failure of the gut barrier is site-specific and inhibitable by growth hormone.

Authors:  Chao Yue; Wei Wang; Wei-Liang Tian; Qian Huang; Ri-Sheng Zhao; Yun-Zhao Zhao; Qiu-Rong Li; Jie-Shou Li
Journal:  Inflamm Res       Date:  2013-01-23       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.